Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paladin Labs has signed an agreement with Allergy Therapeutics to market and distribute Pollinex-R, a short-course immunotherapy vaccine of modified ragweed tyrosine adsorbate, across Canada.
Subscribe to our email newsletter
Takeda Canada and Paladin will co-promote the allergy vaccine product indicated for the treatment of allergic rhinitis due to ragweed pollen for the first eight months prior to initiating selling and distribution activities.
Paladin Labs interim president and CEO Mark Beaudet said, "Pollinex-R is a convenient and effective treatment for the symptoms of ragweed allergy and will expand the range of treatments that Paladin offers to allergy sufferers and health care providers."
The company also has an option to attain distribution rights to Pollinex-R in Sub-Saharan Africa.
Financial terms of the transaction were not revealed.